Crucell and Scripps Research discover and describe broad-spectrum antibodies against influenza B
In a landmark discovery, researchers from Crucell Holland B.V. and The Scripps Research Institute, announced the identification of the first human monoclonal antibodies that appear capable of disabling all influenza B viruses. The discovery, published in the journal Science, addresses a significant missing link in development of universal therapies and a vaccine. The research was conducted by a team of scientists at Crucell, part of the Janssen Pharmaceutical Companies and Scripps Research, along with collaborators from the Centre of Influenza Research at the University of Hong Kong.
"Despite current vaccines and treatments, influenza remains a major medical problem worldwide. There is a strong need for development of new therapies that go beyond treatment or prevention of infection by single strains, especially with the growing problem of resistance to available anti-viral drugs. A broad-spectrum antibody therapy would be of great benefit for protecting people at high risk of dying from influenza such as senior citizens. The immune system deteriorates with age, so the elderly are not adequately protected by current flu vaccines," says Jaap Goudsmit, director of the Crucell Vaccine Institute and coauthor of the study.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
